An attempt to cure type 1 diabetes (T1D) was begun with the implantation of embryonic stem cell into patient's forearm, developed by ViaCyte, San Diego, California, United States. They implanted embryonic stem cell in two patients who are at high-risk of the development of type 1 diabetes (T1D). The implanted stem cells take about three months to mature into islet cells to produce insulin.
To understand safety and efficacy for the full-size embryonic stem cell implantation, trials with a smaller implant were already done on 19 individuals and they are going to conduct the similar procedure on 40 more individuals later this year. Preliminary results of this procedure will be known during the first of 2018.
Researchers are hoping that this procedure can help type 1 diabetes (T1D) patients in managing their condition. Researchers call this procedure as "functional cure" as their therapy is not curing the autoimmune cause of the disease but their procedure is replacing the missing islet cells which produce insulin.
This procedure will improve lives of a number of type 1 diabetes (T1D) patients whose pancreas was unable to produce enough insulin to manage their blood sugar or glucose levels. But the people who have undergone embryonic stem cell need to take immunosuppressive drugs to prevent their immune system in attacking newly implanted cells. The trial investigator was James Shapiro MD, Ph.D, Professor of Surgery, Medicine and Surgical Oncology from the University of Alberta, Edmonton, Alberta, Canada.
Even though an individual was diagnosed with type 1 diabetes (T1D), Professor Mark Peakman says 15 to 20 percent of beta cells remain in the pancreas at the time of diagnosis producing insulin. If the remaining beta cells were protected, the type 1 diabetes (T1D) patient will require less insulin to control their blood sugar or glucose levels. So, researchers wanted to protect the remaining cells from the attack of the immune system by retraining them.
Researchers from the Cardiff University and King's College London (KCL) have conducted MonoPepT1De trial with the support of JDRF and Diabetes UK. The trial results show possibilities to "retrain" patients immune system, which can slowdown the advancement of type 1 diabetes (T1D), thereby protecting the remaining beta cells in the pancreas.
Researchers found that by injecting "small fragments" of protein molecules into the type 1 diabetes (T1D) patient had a marked change in the behavior of the immune system and prevented further attacks of the immune system on insulin-producing beta cells in the pancreas. There is no cure to type 1 diabetes (T1D) but current trial shows the researchers are "heading in the right direction" in finding a solution to type 1 diabetes (T1D). The researchers used peptide technology in the MonoPepT1De trial, which is a safe procedure currently. They also say peptide technology shows marked effect on the immune system.
With the success of MonoPepT1De trial, researchers along with UCB Biopharma are planning to conduct MultipepT1De (a next-generation product) Phase 1b safety study. UCB Biopharma, a Belgian Biopharmaceutical company got exclusive license worldwide from King's College London for MultipepT1De and MonopepT1De.
Lead investigator of the trial was Professor Mark Peakman, MBBS, BSc, MSc, Ph.D, FRCPath, from King's College London and chief investigator of the trial was Professor Colin Dayan, from Cardiff University. The trial findings were published on August 9, 2017, in the journal Science Translational Medicine. Title of the article was "Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.